Gene expression profiling of bone marrow mesenchymal stem cells from Osteogenesis Imperfecta patients during osteoblast differentiation

Kaneto, Carla Martins; Lima, Patricia Santos Pereira; Prata, Karen Lima; Santos, Jane Lima dos; Neto, João Monteiro de Pina; Panepucci, Rodrigo Alexandre; Noushmehr, Houtan; Covas, Dimas Tadeu; Paula, Francisco José Alburquerque de; Silva, Wilson A.

doi:10.1016/j.ejmg.2017.04.003

Cited by 16 publications

(19 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In vitro and in vivo properties, such as proliferation and immunomodulatory properties, have already been compared with other sources of MSCs such as adipose tissue, umbilical cord (Wharton's jelly), placenta, among others. In these comparisons it was found that there is a tendency for MSCs from adipose tissue and Wharton's jelly to be more advantageous in relation to the proliferative and immunomodulatory properties when compared, for instance, to MSCs from bone marrow [58][59][60][61][62][63][64][65] .…”

Section: Discussionmentioning

confidence: 99%

Mesenchymal Stem Cells Immortalization's Protocols and State-of-Art: A Systematic Review and Meta-Analysis

Carvalho¹,

Stricker²,

Irioda³

et al. 2020

Preprint

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) can be derived from several human and animal sources. According to this systematic review, the immortalization of these cells, by viral or gene transfer techniques (plasmid) and non-viral methods, are useful to ensure the reproducibility of the experiments and the prospect of using these cells in clinical studies. The resultant immortalized MSCs cells must undergo through different validation assays in order to prove their safety and phenotypic and genotypic stability; these assays include flow cytometry for specific MSC markers, trilineage differentiation, RT-PCR and qRT-PCR expression analysis for pluripotency genes, karyotype and telomere length and in vivo tumorigenicity assays.

show abstract

Section: Discussionmentioning

confidence: 99%

Mesenchymal Stem Cells Immortalization's Protocols and State-of-Art: A Systematic Review and Meta-Analysis

Carvalho¹,

Stricker²,

Irioda³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…This lowered gene expression results in reduced osteoblast differentiation activity. Also an increase in adipocyte differentiation was observed that may have had a negative effect on the osteogenic differentiation [51].…”

Section: Gene Therapy Techniques Using Stem Cellsmentioning

confidence: 99%

“…This means that PEDF plays a role in the mineralization of osteoblasts within the bone so when it is damaged by mutations in the case of type VI Osteogenesis Imperfecta problems with bone mineralization occur [53]. Another study in 2016 looked at Pigment epithelium-derived factors in induced pluripotent stem cells and their effect on Osteogenesis Imperfecta [51]. The study found that the loss of PEDF in induced pluripotent stem cells of a patient with Osteogenesis Imperfecta leads to a decrease in osteoblast differentiation.…”

Section: Gene Therapy Techniques Using Stem Cellsmentioning

confidence: 99%

The Use of Stem Cells to Treat Osteogenesis Imperfecta

2019

JSCR

View full text Add to dashboard Cite

Osteogenesis Imperfecta is a genetic disorder that affects the body’s ability to create and maintain bone decreasing its strength and durability due to mutations in specific genes that code for the creation of the collagen matrix in the bone structure. Current treatment options available for individuals suffering from Osteogenesis Imperfecta include conventional rehabilitation therapy as well as drug therapy. Recently research has focused on finding a cure using gene therapy, thus having the ability to correct the mutations that cause the weakened collagen fibers. In addition, research is focusing on the use of stem cells that have the ability to differentiate into osteoblasts that can create new and stronger bone. The transplantation of mesenchymal stem cells has been tested to treat the disorder. Positive results have been reported when transplanted prenatally and/or postnatally, through the current use of stem cells and gene therapy using murine models. Additionally, a few trials performed in humans are being planned, in the not too distant future. Once a sufficient number of trials are completed with reported success, treatments using stem cells should be available to patients with Osteogenesis Imperfecta.

show abstract

“…Given the inherent potential of MSCs to contribute to adipose, cartilage and bone tissues [99][100][101][102][103], they have been extensively studied towards their application to regenerate skeletal tissues and their function during skeletal diseases [74,99,[104][105][106][107][108]. Cell studies comparing the differentiation potential of MSCs derived from osteoporotic patients with that of normal MSCs have shown dysregulated osteogenic and adipogenic processes, involving increased adipocyte formation, along with reduced differentiation potential into osteogenic cells [73].…”

Section: Mscs Isolated From Bone Diseasesmentioning

confidence: 99%

Tissue engineered bone mimetics to study bone disorders ex vivo: Role of bioinspired materials

Shih

Varghese

2019

Biomaterials

View full text Add to dashboard Cite

Recent advances in materials development and tissue engineering has resulted in a substantial number of bioinspired materials that recapitulate cardinal features of bone extracellular matrix (ECM) such as dynamic inorganic and organic environment(s), hierarchical organization, and topographical features. Bone mimicking materials, as defined by its self-explanatory term, are developed based on the current understandings of the natural bone ECM during development, remodeling, and fracture repair. Compared to conventional plastic cultures, biomaterials that resemble some aspects of the native environment could elicit a more natural molecular and cellular response relevant to the bone tissue. Although current bioinspired materials are mainly developed to assist tissue repair or engineer bone tissues, such materials could nevertheless be applied to model various skeletal diseases in vitro. This review summarizes the use of bioinspired materials for bone tissue engineering, and their potential to model diseases of bone development and remodeling ex vivo. We largely focus on biomaterials, designed to re-create different aspects of the chemical and physical cues of native bone ECM. Employing these bone-inspired materials and tissue engineered bone surrogates to study bone diseases has tremendous potential and will provide a closer portrayal of disease progression and maintenance, both at the cellular and tissue level. We also briefly touch upon the application of patient-derived stem cells and introduce emerging technologies such as organ-on-chip in disease modeling. Faithful recapitulation of disease pathologies will not only offer novel insights into diseases, but also lead to enabling technologies for drug discovery and new approaches for cell-based therapies.

show abstract

Gene expression profiling of bone marrow mesenchymal stem cells from Osteogenesis Imperfecta patients during osteoblast differentiation

Cited by 16 publications

References 45 publications

Mesenchymal Stem Cells Immortalization's Protocols and State-of-Art: A Systematic Review and Meta-Analysis

Mesenchymal Stem Cells Immortalization's Protocols and State-of-Art: A Systematic Review and Meta-Analysis

The Use of Stem Cells to Treat Osteogenesis Imperfecta

Tissue engineered bone mimetics to study bone disorders ex vivo: Role of bioinspired materials

Contact Info

Product

Resources

About